Advice to Glaxo Operations UK Ltd
Back to listEnquiry
- From
- Glaxo Operations UK Ltd
- Date advice given
- 23 June 2016
- Enquiry type
We have received a notification of the above application by Keuper Gas Storage Ltd.
I have looked at the web site via the suggested links, but I have been unable to find the location this refers to.
Could you please advise this information and I will then be able to contact the relevant person within GlaxoSmithKline.
I think we may be getting these notifications as we had property in Middlewich, Cheshire. If my assumption is correct – we no longer have these premises.
Advice given
You have received this notification regarding the Keuper Gas Storage Project because your organisation is a so called Category 3 person under the 2008 Planning Act (as amended) (PA2008). This means that Glaxo Operations UK Ltd (Glaxo) have a land interest that is impacted by the project and you might therefore be entitled to make a claim under s57(4) of the PA2008 if the Secretary of State for Energy and Climate Change grants the developer a Development Consent Order.
As a Category 3 person the Planning Inspectorate has a legal obligation to notify Glaxo about any procedural decision relating to the examination of the project, such as notifying you about hearings, changes to the time table, and requests for information. However, it does not mean that Glaxo, as a category 3 person, have to respond to any correspondence from the Examining Inspector unless Glaxo think it is in their interest.
The plot of land that relates to Glaxo is Plot no. 52 which can be viewed here:
More details about the plot can be found in the Book of Reference on pages 168 and 179:
https://infrastructure.planninginspectorate.gov.uk/wp-content/ipc/uploads/projects/EN030002/EN030002-000723-4 3 KGSP Book of Reference Rev 2.pdf
Further information on how the Development Consent Order process works can be found in our Advice Note 8.5 Participating in the Examination: http://infrastructure.planninginspectorate.gov.uk/wp-content/uploads/2013/04/Advice-note-8-5v3.pdf